Prot# VX08-950-111: A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, P

Project: Research project

Project Details

StatusFinished
Effective start/end date11/11/0811/11/11

Funding

  • ICON Clinical Research, LLC (VX08-950-111)
  • Vertex Pharmaceuticals Incorporated (VX08-950-111)